A Big Day for Duchenne Muscular Dystrophy Drugmakers

Sarepta Therapeutics and Prosensa shares increase dramatically with separate data releases. Did GlaxoSmithKline make a mistake letting Prosensa go?

Jan 16, 2014 at 8:39PM

Here's something you don't see every day: Sarepta Therapeutics (NASDAQ:SRPT) and Prosensa (NASDAQ:RNA) were both up big today, 40% and 24%, respectively.

The two Duchenne muscular dystrophy drug companies typically act as polar opposites: What's good for one company is usually viewed as bad for the other because they'll compete for patients if both get their drugs approved.

Continuing to work 
Sarepta shot up today after announcing 120-week data from its endless phase 2 trial. After six months of additional treatment with its Duchenne muscular dystrophy drug, eteplirsen, since the last update, the boys in the trial continue to remain stable.

After treatment for 96 weeks, the patients that could take the test walked 17.5 meters less in six minutes than they did at the start of the trial. In the newest measurement, the decline was only 13.9 meters from baseline. Technically, that's an improvement, but it's probably not significant. Considering the eventual decline for the natural course of the disease, stable is just fine.

Four patients in the trial got placebo for the first 24 weeks to act as a control group, and then started to receive eteplirsen. If you measure from 36 weeks, after the drug would have started working, through week 120, those patients declined 9.5 meters. That's actually a substantial improvement compared to the 96-week data, which had a decline of 18.5 because one of the boys was still recovering from a broken ankle. The fact that he recovered at all is a testament that the drug is working.

Might actually work 
Prosensa is in a much different position than Sarepta, having seen its Duchenne muscular dystrophy drug, drisapersen, fail a phase 3 trial, and its partner, GlaxoSmithKline (NYSE:GSK), hand back rights to the drug.

But the biotech said today that drisapersen seems to be helping boys who are seven better than older boys. In one of the phase 2 trials, the treatment difference -- the difference in decline seen in patients receiving drisapersen compared to placebo -- was 38 meters for the younger subset. In the larger phase 3 trial, the difference was 21 meters. Neither was statistically significant, but if you combine the two trials, you get a treatment difference of 24 meters and enough subjects to conclude that it's statistically significant.

Hand waving? Absolutely -- you've got a subset analysis followed and a meta-analysis. While it makes sense the drug would work better earlier in the disease progression, you have to take the data with a grain of salt. The FDA will almost certainly want a new trial in younger patients to confirm the results.

Of course, when your drug looks dead, any inclination that the drug is working will breathe life into a stock. Prosensa's shares were up 24% today, but it still only has a market cap of $250 million, compared to Sarepta's $1 billion market cap.

Better buy?
For long-term investors, I think Sarepta is a better buy even though it's four times as expensive. With every new report from the ongoing phase 2 trial, investors become even more confident that eteplirsen will pass its phase 3 trial.

With data this good, the FDA might even change its current opinion, and accept the current data for an accelerated approval. While a bit of a long shot, some of today's price increase is probably based on that hope. In the short term, shares could come down a little if Sarepta confirms that the FDA wants a phase 3 trial, leading to a delay in approval by more than a year.

Our top pick in 2014
There's a huge difference between a good stock and a stock that can make you rich. The Motley Fool's chief investment officer has selected his No. 1 stock for 2014, and it's one of those stocks that could make you rich. You can find out which stock it is in the special free report: "The Motley Fool's Top Stock for 2014." Just click here to access the report and find out the name of this under-the-radar company.

Fool contributor Brian Orelli has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

1 Key Step to Get Rich

Our mission at The Motley Fool is to help the world invest better. Whether that’s helping people overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we can help.

Feb 1, 2016 at 4:54PM

To be perfectly clear, this is not a get-rich action that my Foolish colleagues and I came up with. But we wouldn't argue with the approach.

A 2015 Business Insider article titled, "11 websites to bookmark if you want to get rich" rated The Motley Fool as the #1 place online to get smarter about investing.

"The Motley Fool aims to build a strong investment community, which it does by providing a variety of resources: the website, books, a newspaper column, a radio [show], and [newsletters]," wrote (the clearly insightful and talented) money reporter Kathleen Elkins. "This site has something for every type of investor, from basic lessons for beginners to investing commentary on mutual funds, stock sectors, and value for the more advanced."

Our mission at The Motley Fool is to help the world invest better, so it's nice to receive that kind of recognition. It lets us know we're doing our job.

Whether that's helping the entirely uninitiated overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we want to provide our readers with a boost to the next step on their journey to financial independence.

Articles and beyond

As Business Insider wrote, there are a number of resources available from the Fool for investors of all levels and styles.

In addition to the dozens of free articles we publish every day on our website, I want to highlight two must-see spots in your tour of fool.com.

For the beginning investor

Investing can seem like a Big Deal to those who have yet to buy their first stock. Many investment professionals try to infuse the conversation with jargon in order to deter individual investors from tackling it on their own (and to justify their often sky-high fees).

But the individual investor can beat the market. The real secret to investing is that it doesn't take tons of money, endless hours, or super-secret formulas that only experts possess.

That's why we created a best-selling guide that walks investors-to-be through everything they need to know to get started. And because we're so dedicated to our mission, we've made that available for free.

If you're just starting out (or want to help out someone who is), go to www.fool.com/beginners, drop in your email address, and you'll be able to instantly access the quick-read guide ... for free.

For the listener

Whether it's on the stationary exercise bike or during my daily commute, I spend a lot of time going nowhere. But I've found a way to make that time benefit me.

The Motley Fool offers five podcasts that I refer to as "binge-worthy financial information."

Motley Fool Money features a team of our analysts discussing the week's top business and investing stories, interviews, and an inside look at the stocks on our radar. It's also featured on several dozen radio stations across the country.

The hosts of Motley Fool Answers challenge the conventional wisdom on life's biggest financial issues to reveal what you really need to know to make smart money moves.

David Gardner, co-founder of The Motley Fool, is among the most respected and trusted sources on investing. And he's the host of Rule Breaker Investing, in which he shares his insights into today's most innovative and disruptive companies ... and how to profit from them.

Market Foolery is our daily look at stocks in the news, as well as the top business and investing stories.

And Industry Focus offers a deeper dive into a specific industry and the stories making headlines. Healthcare, technology, energy, consumer goods, and other industries take turns in the spotlight.

They're all informative, entertaining, and eminently listenable ... and I don't say that simply because the hosts all sit within a Nerf-gun shot of my desk. Rule Breaker Investing and Answers contain timeless advice, so you might want to go back to the beginning with those. The other three take their cues from the market, so you'll want to listen to the most recent first. All are available at www.fool.com/podcasts.

But wait, there's more

The book and the podcasts – both free ... both awesome – also come with an ongoing benefit. If you download the book, or if you enter your email address in the magical box at the podcasts page, you'll get ongoing market coverage sent straight to your inbox.

Investor Insights is valuable and enjoyable coverage of everything from macroeconomic events to investing strategies to our analyst's travels around the world to find the next big thing. Also free.

Get the book. Listen to a podcast. Sign up for Investor Insights. I'm not saying that any of those things will make you rich ... but Business Insider seems to think so.

Compare Brokers